Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | CBFB | Q13951 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3644544 | 0.93 | PPARG (0.33) | PPARGPPARACYP4F2CYP4A11FYN | |
| SCHEMBL1799455 | 0.87 | PPARG (0.34) | PPARGPPARACYP4F2CYP4A11FYN | |
| SCHEMBL1799643 | 0.84 | PPARG (0.35) | PPARGPPARACYP4F2CYP4A11FYN | |
| SCHEMBL5132892 | 0.78 | PPARG (0.35) | PPARGPPARA | |
| SCHEMBL12057944 | 0.78 | PIK3CD (0.38) | FYNHRH3MBOAT4 | |
| SCHEMBL12036823 | 0.78 | FYN (0.34) | FYNHRH3 | |
| SCHEMBL12036832 | 0.76 | FYN (0.40) | FYNCBFBHRH3 | |
| SCHEMBL29987089 | 0.75 | PREP (0.36) | PPARGPPARAHDAC1HDAC6HDAC5 | |
| SCHEMBL15968422 | 0.75 | PREP (0.36) | PPARGPPARAHDAC1HDAC6HDAC5 | |
| SCHEMBL10239026 | 0.75 | MCHR1 (0.35) | FYNHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633315-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2167471-B1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8552181-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130072483-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8173810-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8163909-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7951838-B2 | Substituted spirocyclic chromanamine compounds as Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100317668-A1 | SUBSTITUTED PYRANO [2,3-B] PYRIDINAMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7803809-B2 | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2167471-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009064418-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090036478-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2008147544-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147547-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | BACE1, APP, BACE2 | PPARG 1648/4885PPARA 1525/4885CYP4F2 1519/4885 |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | BACE1, BACE2, APP | PPARG 3522/4885PPARA 2943/4885CYP4F2 1741/4885 |
| US-20100317668-A1 | SUBSTITUTED PYRANO [2,3-B] PYRIDINAMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, APP, BACE2 | PPARG 1648/4885PPARA 1525/4885CYP4F2 1519/4885 |
| US-20090036478-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | BACE1, BACE2, APP | PPARG 3603/4885PPARA 2941/4885CYP4F2 2726/4885 |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | PPARG 3647/4885PPARA 3036/4885CYP4F2 2645/4885 |
| US-20130072483-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | PPARG 3603/4885PPARA 2941/4885CYP4F2 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.